Drug profile

The FDA adverse-event record for Canine Infl H3N2 / H3N8 Kv

63 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Infl H3N2 / H3N8 Kv. See the species affected, top reactions, and outcomes below.

63
adverse-event reports
17.5%
death-coded share
Dog
most-reported species
21
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
63
Total Reports
11
Deaths Reported
17.5%
Death Rate

Active Ingredients

Canine Infl H3N2 / H3N8 Kv

Administration Routes

SubcutaneousUnknownSubconjunctival

Species Affected

Dog 63

Most Affected Breeds

Crossbred Canine/dog 21
Shepherd Dog - Australian 5
Retriever - Golden 4
Boxer (German Boxer) 3
Pit Bull 3
Beagle 3
Dog (other) 2
Papillon - Spaniel - Continental Toy (with erect ears or with dropped ears (Phaléne)) 2
Terrier (unspecified) 2
Terrier - Yorkshire 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 21
Vomiting 16
Emesis (multiple) 14
Diarrhoea 13
Anorexia 7
Death by euthanasia 6
Neutrophilia 6
Other abnormal test result NOS 5
Bloody diarrhoea 5
Death 5
Leucocytosis NOS 5
Weight loss 4

Outcome Breakdown

Ongoing
24 (38.1%)
Recovered/Normal
21 (33.3%)
Outcome Unknown
7 (11.1%)
Euthanized
6 (9.5%)
Died
5 (7.9%)

Canine Infl H3N2 / H3N8 Kv Adverse Event Insights

63 reports name Canine Infl H3N2 / H3N8 Kv; 11 recorded a death outcome (17.5% of reported events, not a population-level mortality rate). Active ingredient: Canine Infl H3N2 / H3N8 Kv. Administration routes: Subcutaneous, Unknown, Subconjunctival.

By species: Dog (63 reports). By breed: Crossbred Canine/dog (21), Shepherd Dog - Australian (5), Retriever - Golden (4).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (21), Vomiting (16), Emesis (multiple) (14), Diarrhoea (13). Outcome, 63 coded reports: Ongoing leads at 38.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.